Biomay Technology Platform

Solutions for Better Allergy Therapy

Various innovative approaches to allergy immunotherapy and allergy prophylaxis are the core of Biomay's proprietary technology platform. These core technologies are complemented by supporting technologies, such as adjuvants particularly tailored for allergy vaccination. Together, they enable the development of novel products for allergen specific immunotherapy (SIT) with significantly improved safety and clinical efficacy. Individual technologies as well as NBEs derived from the platform are protected by a broad patent portfolio.

For more information please click the diagram.

Our technology platform provides the key to a new generation of allergy vaccines and opens up the door to allergy prophylaxis. Out-licensed molecules from this platform have successfully passed phase IIb clinical trials for allergy vaccines (see Product Pipeline).

• Wild type recombinant allergens: Valenta and Niederberger, J. Allergy Clin. Immunol. 2007
• Hypoallergenic proteins and derivatives: Valenta, Nature Rev. Immunol. 2002
• B-cell peptides: Focke et al., FASEB J. 2001
• Specific antibodies: Flicker et  al., Eur. J. Immunol. 2002
• RNA vaccines: Thalhamer, Expose RNA Vaccines 2008
• Cell based therapy: Baranyi et al., Eur. J. Immunol. 2008

NEWS